[ad_1]
Los Angeles, USA, July 22, 2021 (Global News Agency)- Analysis of recent clinical trials in the treatment of myasthenia gravis
About 15 major companies are developing treatments for myasthenia gravis. Argenx’s drug candidates are in the pre-registration stage. The increase in the number of clinical trials is expected to promote the treatment of myasthenia gravis. Emerging therapies currently include biological agents and molecules with new mechanisms of action.
DelveInsight’s “Myasthenia gravis pipeline insightThe report provides information on 15+ Company and 15+ Pipeline drugs in myasthenia gravis pipeline landscape. It includes an overview of myasthenia gravis pipeline drugs, including clinical and non-clinical stage products. It also includes evaluation of the treatment of myasthenia gravis by product type, stage, route of administration, and molecular type, and further highlights inactive myasthenia gravis pipeline products.
Some key points Myasthenia Gravis Pipeline Report
- Big companies such as Agenx, Alexion Pharmaceuticals, RemeGen, Horizon Pharma, UCB Biopharma, DAS Therapeutics, AnTolRx, Cabaletta Bio, CytoDyn, NMD Pharma, Cartesian Therapeutics, Harbour BioMed, Kashiv Biosciences, Ahead Therapeutics, And others are developing potential drug candidates to improve treatment options for myasthenia gravis.
- In March 2021, Agenx Announcing that FDA accepts BLA applications Gatimod Treatment of systemic myasthenia gravis.
- Agenx Also expected to submit an application Tigamod It will be submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in the first half of 2021 and to the European Medicines Agency (EMA) in the second half of 2021.
- In March 2021, Horizon therapy Announcing the completion of the acquisition Vera Bio
- Organic Cavaletta Is developing Musk Carter Designed to treat myasthenia gravis (MG), an autoimmune disease that affects neuromuscular junctions and can cause movement disorders, muscle weakness, and respiratory failure.
- Descartes-08 It is the first CAR T cell therapy for autoimmune diseases.It is under development Descartes therapy Used to treat myasthenia gravis. Descartes-08 contains autologous CD8+ T cells that are modified by RNA chimeric antigen receptor (CAR) that binds to B cell maturation antigen (BCMA). BCMA is widely expressed by plasma cell clones that produce pathogenic autoantibodies. Descartes-08 binds and kills these cells, eliminating the source of autoantibodies.
- RC18 Studying Phase III clinical trials RemGen. It is a new first-class TACI-Fc fusion protein, used to treat B cell-mediated autoimmune diseases.
Get an overview of the pipeline landscape@ Analysis of clinical trials of myasthenia gravis
Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes skeletal muscle weakness, which worsens after the active period and improves after the rest period.
New drug for myasthenia gravis
- Efgartigimod: Argenx
Gatimod It is an investigative antibody fragment designed to reduce disease-causing immunoglobulin G (IgG) antibodies and inhibit the IgG recycling process. The results of a phase III clinical trial (ADAPT) show that efgartigimod treatment provides clinically significant improvements in the strength and quality of life of systemic myasthenia gravis (gMG). Efgartigimod is under review by the US Food and Drug Administration (FDA), December 17, 2021, the Prescription Drug User Fee Act (PDUFA) target action date
- Inebilizumab: Horizon Therapy
Nibizumab It is a humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody (mAb) that can bind to the B cell specific surface antigen CD19.It is currently at The third phase The developmental stage of treatment of myasthenia gravis is being changed by Horizon Therapy (Viela Bio).
- Ravulizumab: Alexion Pharmaceuticals
Leivuzumab It is the first and only long-acting C5 complement inhibitor. The drug works by blocking the C5 protein in the terminal complement cascade, which is part of the human immune system. When activated in an uncontrolled manner, the complement cascade overreacts, causing the body to attack its healthy cells. Alixiong Pharmaceutical Reported positive top-line results The third phase A study to evaluate the safety and effectiveness of ravulizumab in adults with generalized myasthenia gravis (gMG). The company plans to submit regulatory documents in the United States, the European Union and Japan at the end of 2021 or early 2022 based on the results of P-III.
- Inebilizumab: Horizon Therapy
The full story can be found on Benzinga.com
[ad_2]
Source link
